Skip to main content
. 2018 Oct 11;10(11):e8799. doi: 10.15252/emmm.201708799

Figure 2. Rapamycin improves the biochemical phenotype of Cox15 sm/sm skeletal muscles.

Figure 2

  • A
    Spectrophotometric activities of the respiratory chain (n = 4–5/group). CS: citrate synthase; cIV: complex IV. Black: untreated WT; gray: rapamycin‐treated WT; red: untreated Cox15 sm/sm; blue: rapamycin‐treated Cox15 sm/sm. Error bars represent SEM. The asterisks represent the significance levels calculated by two‐way ANOVA with Tukey’s correction: ****P  <  0.0001 (CS: WT versus Cox15 sm/sm), ***P = 0.0010 (CS: Cox15 sm/sm versus Cox15 sm/sm rapamycin), ***P = 0.005 (cIV: Cox15 sm/sm versus WT), ****P  <  0.0001 (cIV/CS: WT versus Cox15 sm/sm), **P = 0.0060 (cIV/CS: Cox15 sm/sm rapamycin versus Cox15 sm/sm).
  • B
    Western blot immunovisualization of subunits of the respiratory complexes. Note the increased protein levels in Cox15 sm/sm versus WT samples, which are reduced to normal levels upon rapamycin treatment. Additional samples were run on a separate gel (not shown).
  • C
    BNGE in‐gel activity for cIV. Sc: supercomplexes. Note that the COX reaction is slightly increased in rapamycin‐treated versus untreated Cox15 sm/sm samples.
  • D
    Immunoblot of 1D‐BNGE using an anti‐cIV antibody (COX1). Note that COX amount is slightly increased in rapamycin‐treated versus untreated Cox15 sm/sm muscles. SDHB was used as a loading control.
  • E
    State III (succinate‐driven) oxygen consumption (n = 3/group). Error bars represent SEM. The asterisks represent the significance levels calculated by unpaired, two‐tailed Student's t‐test: **P = 0.0016 (WT versus Cox15 sm/sm); *P = 0.047 (Cox15 sm/sm versus Cox15 sm/sm+rapamycin).
  • F
    Analysis of mtDNA amount (n = 9/group). Error bars represent SEM. The asterisks represent the significance levels calculated by one‐way ANOVA with Tukey's correction: **P = 0.0020; *P = 0.0296.